The inflammatory proteome, obesity, and medical weight loss and regain in humans.
Journal
Obesity (Silver Spring, Md.)
ISSN: 1930-739X
Titre abrégé: Obesity (Silver Spring)
Pays: United States
ID NLM: 101264860
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
12
08
2022
received:
12
06
2022
accepted:
16
08
2022
pmc-release:
01
01
2024
pubmed:
6
11
2022
medline:
23
12
2022
entrez:
5
11
2022
Statut:
ppublish
Résumé
Weight regain occurs after medical weight loss via mechanisms of post-weight-loss "metabolic adaptation." The relationship of inflammatory proteins with weight loss/regain was studied to determine a role for inflammation in metabolic adaptation. Seventy-four proteins central to inflammation and immune regulation (Olink) were analyzed in plasma from up to 490 participants in a trial of medical weight-loss maintenance. Cross-sectional and longitudinal associations of proteins with weight were measured using linear and mixed effects regression models and t testing, with replication in the Framingham Heart Study. Broad changes in the inflammatory proteome were observed among the study cohort (60% women, 35% African American) with initial weight loss of ≈8 kg from a median 94 kg at study entry (33/74 proteins; 7 increased; 26 decreased), many of which tracked with weight regain of median ≈2 kg over the next 30 months. Ten proteins were associated with different rates of weight regain, some specifying pathways of chemotaxis and innate immune responses. Several of the observed protein associations were also linked to prevalent obesity in the Framingham Heart Study. Broad changes in the inflammatory proteome track with changes in weight and may identify specific pathways that modify patterns of weight regain.
Identifiants
pubmed: 36334095
doi: 10.1002/oby.23587
pmc: PMC9923277
mid: NIHMS1836660
doi:
Substances chimiques
Proteome
0
Types de publication
Clinical Trial
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
150-158Subventions
Organisme : NHLBI NIH HHS
ID : K23 HL138260
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL156975
Pays : United States
Organisme : NHLBI NIH HHS
ID : R21 HL147831
Pays : United States
Informations de copyright
© 2022 The Obesity Society.
Références
Sci Rep. 2017 Dec;7(1):130
pubmed: 28273932
PLoS One. 2014 Apr 22;9(4):e95192
pubmed: 24755770
N Engl J Med. 2011 Oct 27;365(17):1597-604
pubmed: 22029981
Mol Syst Biol. 2016 Dec 22;12(12):901
pubmed: 28007936
J Clin Invest. 2003 Dec;112(12):1821-30
pubmed: 14679177
J Immunol. 1998 Jul 15;161(2):927-32
pubmed: 9670971
Diabetes. 2020 Feb;69(2):181-192
pubmed: 31712321
Lancet. 2014 Mar 15;383(9921):999-1008
pubmed: 24084292
JAMA. 2008 Mar 12;299(10):1139-48
pubmed: 18334689
Obesity (Silver Spring). 2016 Aug;24(8):1612-9
pubmed: 27136388
J Clin Invest. 1998 Apr 15;101(8):1557-64
pubmed: 9541484
N Engl J Med. 2021 Mar 18;384(11):989-1002
pubmed: 33567185
Med Clin North Am. 2018 Jan;102(1):183-197
pubmed: 29156185
Cell. 2019 Apr 18;177(3):587-596.e9
pubmed: 31002795
Lancet. 1998 Jul 18;352(9123):167-72
pubmed: 9683204
Int J Obes (Lond). 2015 Aug;39(8):1188-96
pubmed: 25896063
Immunology. 2018 May 2;:
pubmed: 29722014
Anim Genet. 2017 Aug;48(4):386-394
pubmed: 28568315
J Obes. 2014;2014:614519
pubmed: 25197563
Nature. 1998 Feb 19;391(6669):795-9
pubmed: 9486650
Mol Cell Proteomics. 2021;20:100168
pubmed: 34715355
Front Bioeng Biotechnol. 2020 Jan 24;8:6
pubmed: 32039191
Sci Rep. 2020 May 13;10(1):7913
pubmed: 32404980
JAMA Cardiol. 2020 Mar 1;5(3):40-48
pubmed: 31913407
N Engl J Med. 2004 Dec 23;351(26):2683-93
pubmed: 15616203
Lancet. 2016 May 7;387(10031):1947-56
pubmed: 26868660
Am J Clin Nutr. 2008 Oct;88(4):906-12
pubmed: 18842775
JAMA. 2021 Apr 13;325(14):1414-1425
pubmed: 33755728
Diabetes. 2019 Feb;68(2):318-323
pubmed: 30257977
PLoS One. 2016 Dec 19;11(12):e0166048
pubmed: 27992443
J Immunol. 1995 Mar 15;154(6):2612-23
pubmed: 7876536
Dig Dis Sci. 2020 Apr;65(4):1144-1154
pubmed: 31385097